Myriad Genetics Issues 2022 Environmental, Social and Governance Report
19 Setembro 2023 - 8:00AM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today released its second annual
Environmental, Social and Governance report, highlighting key
efforts that reflect its commitment to conduct operations as a
responsible, equitable and sustainable partner in the healthcare
industry.
“At Myriad, we understand the important role we play in
advancing health equity and social justice,” said Paul Diaz,
president and chief executive officer, Myriad Genetics. “We also
recognize our responsibility to operate in harmony with the
environment which includes efforts to minimize our impact on the
climate. In our 2022 ESG report, we highlight how these topics are
directly linked to our purpose and values, and share updates on our
progress and plans to remain a transparent and accountable
corporate citizen.”
Key highlights from the report include:
- Advancing scientific research and patient
care. Myriad is sharing data for use in clinical care and
scientific research in several ways, such as hereditary cancer and
prenatal data with ClinVar and hereditary cancer data with the
California and Georgia SEER registries. Myriad also established the
Precise Treatment Registry, which gives clinicians access to
clinical insights across patient populations and the ability to
explore hypotheses in real time.
- Broadening affordable access to genetic testing for all
patient populations. In 2022, Myriad provided more
than $31 million in financial assistance to 63,000+ uninsured and
underinsured patients, offering financial assistance, free testing,
and direct pay options to those in need.
- Progressing diversity, equity and inclusion
efforts. Myriad is committed to recruiting, hiring
and promoting team members from diverse backgrounds. At the end of
2022, women made up 62% of the Myriad workforce and 45% of
leadership roles.
- Protecting our environment. Since 2019, Myriad
has recycled approximately 102 tons of plastic from its Salt Lake
City laboratories, including 31.4 tons of plastic during 2022.
Myriad is working to bring its Labs of the Future online which will
transform how it conducts operations and will significantly reduce
its environmental footprint.
For more information about Myriad’s ESG efforts, read the 2022
report
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements that the company’s laboratories of the future will
transform how it conducts operations and significantly reduce its
environmental footprint. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Media Contact: |
Investor Contact: |
Glenn Farrell |
Matt Scalo |
(385) 318-3718 |
(801) 584-3532 |
PR@myriad.com |
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024